Rapport Therapeutics, Inc. Common Stock (RAPP) - Stock Analysis
Last updated: Apr 25, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Strong Liquidity ⢠No Revenue ⢠Cash Burn RAPP has a very strong, lightly levered balance sheet and ample liquidity, but the absence of revenue, persistent losses, and negative free cash flow make its financial profile fundamentally weak despite the cash and investments.
Price Behavior
Key Price Behavior Insights: ⢠Higher lows ⢠Fast breakout ⢠Consolidation phase Support Level: $36.10-$36.40, deeper support near $34.60 Resistance Level: $39.50-$39.70 RAPP has been in a constructive uptrend over the last month, but after a sharp mid-April surge it is now consolidating above mid-30s support and needs to hold $34.60 to keep the breakout intact.
Sentiment & News
Key News Insights: ⢠Analyst Upgrade ⢠Seizure Reduction ⢠Strong Tolerability RAPP's recent headlines are constructive, with upgraded analyst sentiment and encouraging Phase 2 RAP-219 follow-up data showing sustained seizure reduction and good tolerability.
AI Summary
RAPP has shifted from a speculative neuroscience name to a potentially differentiated epilepsy platform, with RAP-219's durability/tolerability and a cash-rich balance sheet supporting a credible runway into Phase 3, but the stock now hinges almost entirely on whether late-stage data can confirm the current signal before momentum and valuation outpace fundamentals.
Description
Rapport Therapeutics is a clinical-stage biopharmaceutical company developing small-molecule therapies for central nervous system disorders. Its lead candidate, RAP-219, is a high-affinity inhibitor of TARPy8-containing AMPA receptors being evaluated for focal epilepsy and other CNS indications; the pipeline also includes an additional TARPy8 program and nicotinic acetylcholine receptor projects targeting chronic pain and hearing disorders. The company was incorporated in 2022, renamed from Precision Neuroscience NewCo in October 2022, and is based in Boston, Massachusetts.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 15 | Sep 22 | RAPP | Rapport Therapeutics, Inc. Common Stock | Rapport Therapeutics surged nearly 200% after strong Phase 2a trial results and secured $250 million in capital, supported by positive clinical data and recent dilution-driven volatility, combining compelling catalysts with technical strength to represent a hot idea in the near term. | Closed | +5.6% |